Cholinergic antagonist 3-quinuclidinyl benzilate - Impact on learning and memory in Wistar rats

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F14%3A43875128" target="_blank" >RIV/60162694:G44__/14:43875128 - isvavai.cz</a>
Result on the web
<a href="http://www.sciencedirect.com/science/article/pii/S0166432814001430" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0166432814001430</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.bbr.2014.03.001" target="_blank" >10.1016/j.bbr.2014.03.001</a>

Result language
angličtina
Original language name
Cholinergic antagonist 3-quinuclidinyl benzilate - Impact on learning and memory in Wistar rats
Original language description
3-Quinuclidinyl benzilate (QNB) represents a non-selective, competitive antagonist of cholinergic receptors, which has been previously used to generate cognitive deficits in animal models of neurodegenerative disorders. The aim of this study was evaluation of QNB potency for creation of cognitive impairment during the acquisition, consolidation and retrieval stages of learning and memory in rats. Male Wistar rats were subjected to a water maze task with hidden platform and a step-through passive avoidance task. The water maze test was carried out in two separate experiments focused on spatial learning (acquisition test) and long-term spatial memory (retrieval test). QNB doses (0.5, 1.0, 2.0 and 5.0 mg kg(-1)) were administered to rats intraperitoneallybefore training sessions (acquisition test) or before probe trial (retrieval test). A QNB dose of 2.0 mg kg(-1) was administered to rats in the passive avoidance task before training (acquisition test), immediately post-training (consoli
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FH - Neurology, neuro-surgery, nuero-sciences
OECD FORD branch
—

Project
<a href="/en/project/GAP303%2F12%2F0611" target="_blank" >GAP303/12/0611: Neurobehavioral evaluation of potential Alzhemier`s disease drugs</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)